Deciphera Pharmaceuticals, Inc. DCPH
We take great care to ensure that the data presented and summarized in this overview for Deciphera Pharmaceuticals, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding DCPH
View all-
Black Rock Inc. New York, NY5.99MShares$153 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY5.9MShares$151 Million1.26% of portfolio
-
Redmile Group, LLC San Francisco, CA5.3MShares$135 Million3.28% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY5.13MShares$131 Million1.67% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.57MShares$117 Million0.0% of portfolio
-
State Street Corp Boston, MA3.1MShares$79.1 Million0.0% of portfolio
-
Goldman Sachs Group Inc New York, NY1.96MShares$50.1 Million0.01% of portfolio
-
Dimensional Fund Advisors LP Austin, TX1.61MShares$41 Million0.01% of portfolio
-
Morgan Stanley New York, NY1.54MShares$39.3 Million0.0% of portfolio
-
Polar Capital Holdings PLC London, X01.5MShares$38.3 Million0.15% of portfolio
Latest Institutional Activity in DCPH
Top Purchases
Top Sells
About DCPH
Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.
Insider Transactions at DCPH
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 22
2024
|
Brightstar Associates LLC > 10% Shareholder |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Direct |
48,136
+0.21%
|
$0
$0.01 P/Share
|
|
Feb 16
2024
|
Daniel C. Martin Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
2,267
-3.95%
|
$34,005
$15.62 P/Share
|
|
Feb 16
2024
|
Jama Pitman SVP, Chief Development Officer |
SELL
Open market or private sale
|
Direct |
2,267
-3.22%
|
$34,005
$15.62 P/Share
|
|
Feb 16
2024
|
Thomas Patrick Kelly Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,010
-3.61%
|
$45,150
$15.62 P/Share
|
|
Feb 16
2024
|
Matthew L Sherman EVP & Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,615
-2.35%
|
$39,225
$15.62 P/Share
|
|
Feb 15
2024
|
Daniel C. Martin Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
9,725
+14.49%
|
-
|
|
Feb 15
2024
|
Dashyant Dhanak EVP & Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
17,275
+9.85%
|
-
|
|
Feb 15
2024
|
Jama Pitman SVP, Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
19,725
+13.17%
|
-
|
|
Feb 15
2024
|
Thomas Patrick Kelly Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
17,275
+17.17%
|
-
|
|
Feb 15
2024
|
Matthew L Sherman EVP & Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
17,275
+13.43%
|
-
|
|
Feb 07
2024
|
Brightstar Associates LLC > 10% Shareholder |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Direct |
914,001
+3.81%
|
$0
$0.01 P/Share
|
|
Jan 16
2024
|
Daniel C. Martin Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,624
-3.3%
|
$22,736
$14.47 P/Share
|
|
Jan 16
2024
|
Thomas Patrick Kelly Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,435
-3.55%
|
$34,090
$14.47 P/Share
|
|
Jan 16
2024
|
Jama Pitman SVP, Chief Development Officer |
SELL
Open market or private sale
|
Direct |
1,624
-3.11%
|
$22,736
$14.47 P/Share
|
|
Jan 16
2024
|
Matthew L Sherman EVP & Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,435
-2.52%
|
$34,090
$14.47 P/Share
|
|
Dec 13
2023
|
Matthew L Sherman EVP & Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,792
-2.81%
|
$41,880
$15.37 P/Share
|
|
Dec 13
2023
|
Daniel C. Martin Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,727
-3.39%
|
$25,905
$15.37 P/Share
|
|
Dec 13
2023
|
Jama Pitman SVP, Chief Development Officer |
SELL
Open market or private sale
|
Direct |
1,662
-3.09%
|
$24,930
$15.37 P/Share
|
|
Dec 13
2023
|
Thomas Patrick Kelly Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,792
-3.92%
|
$41,880
$15.37 P/Share
|
|
Dec 13
2023
|
Steven L. Hoerter President and CEO |
SELL
Open market or private sale
|
Direct |
30,664
-29.65%
|
$459,960
$15.37 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 402K shares |
|---|---|
| Open market or private purchase | 10K shares |
| Exercise of in-the-money or at-the-money derivatives securities | 962K shares |
| Open market or private sale | 115K shares |
|---|